Nomad Power Solutions (NMAD) Research & Development (2010 - 2026)
Nomad Power Solutions (NMAD) posted Research & Development of $62250.0 for Q2 2026, up 19.44% on a QoQ basis from $52118.0 in Q4 2025, and up 2.64% year-over-year from $60648.0 in Q2 2025.
Analysis
Nomad Power Solutions (NMAD) Research & Development (2010 - 2026) Analysis & Trends
Nomad Power Solutions has reported Research & Development for 17 years, with the latest figure at $62250.0 in Q2 2026.
- On a quarterly basis, Research & Development rose 2.64% year-over-year to $62250.0 in Q2 2026; TTM through Jun 2026 was $225712.0, a 58.85% decrease from a year earlier, with the FY2025 full-year figure at $254919.0, down 64.9% from the prior year.
- Research & Development was $62250.0 for Q2 2026 at Nomad Power Solutions, up from $52118.0 in the prior quarter.
- The five-year high for Research & Development was $458450.0 in Q1 2022, with the low at $34830.0 in Q4 2024.
- Average Research & Development over 5 years is $193574.6, with a median of $149071.0 recorded in 2023.
- The sharpest annual moves came in 2024 and 2025: Research & Development surged 172.96% in 2024, then sank 85.98% in 2025.
- Over 5 years, Research & Development stood at $453620.0 in 2022, then slumped by 67.14% to $149071.0 in 2023, then sank by 76.64% to $34830.0 in 2024, then surged by 49.64% to $52118.0 in 2025, then climbed by 19.44% to $62250.0 in 2026.
- The last three Research & Development figures came in at $62250.0 (Q2 2026), $52118.0 (Q4 2025), and $50696.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1.87 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 1.76 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 993.80 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.63 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -486.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 651.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 529.60 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 202.02 Mn |
| 10 | Nomad Power Solutions | 49.59 Mn | 49.59 Mn | - | 62,250.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 62,250.00 |
| Dec 31, 2025 | 52,118.00 |
| Sep 30, 2025 | 50,696.00 |
| Jun 30, 2025 | 60,648.00 |
| Mar 31, 2025 | 91,457.00 |
| Dec 31, 2024 | 34,830.00 |
| Sep 30, 2024 | 361,630.00 |
| Jun 30, 2024 | 210,708.00 |
| Mar 31, 2024 | 119,064.00 |
| Dec 31, 2023 | 149,071.00 |
| Sep 30, 2023 | 132,487.00 |
| Jun 30, 2023 | 427,457.00 |
| Mar 31, 2023 | 189,085.00 |
| Dec 31, 2022 | 453,620.00 |
| Sep 30, 2022 | 272,388.00 |
| Jun 30, 2022 | 164,810.00 |
| Mar 31, 2022 | 458,450.00 |
| Dec 31, 2021 | 803,654.00 |
| Sep 30, 2021 | 227,181.00 |
| Jun 30, 2021 | 262,415.00 |